The Global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market size is valued at USD 1.0 billion in 2023 and is predicted to reach USD 2.33 billion by the year 2031 at an 11.31% CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- Innovations in site-specific conjugation and novel linker chemistries contribute to the development of more effective and reliable ADCs.
- Collaboration between pharmaceutical companies, biotechnology firms, and academic institutions fosters innovation and accelerates the development of ADCs.
- North America dominated the market and accounted for a global revenue share in 2023.
- The biological mechanisms underlying ADCs' efficacy and potential side effects are not yet fully understood. This limited understanding can lead to unpredictable clinical outcomes and poses challenges in optimizing ADC designs.
In recent years cancer has cancer has emerged as a major public health problem in the world and a few of the most common forms are breast cancer, lung cancer, prostate cancer and leukemia. Antibody drug conjugates (ADCs) signify a promising and an efficient strategy for targeted cancer therapy. ADCs are being developed as a new class of highly potent bio-pharmaceutical drugs, and characterized as an advanced therapeutic application that has collective properties of monoclonal antibodies (mAbs) with the potent small molecule drugs (cytotoxin). At present times, as research, development and approval of ADC-based technology moves forward, ADC-based chemotherapy drugs will impact the current chemotherapy market. It is further expected to improve the quality of life for cancer patients and influence research and development in other pharmaceutical markets.
The factor which is significantly boosting the growth of the global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies market is the rise in the incidence of cancer coupled with growing geriatric population. The increase in obese population and increasing research activities on antibody therapies is catalyzing the growth of Antibody drug conjugates industry. Also, increased investments by governments and private organizations for the preclinical research, and the cumulative research on oncology diseases are contributing to the growth of the global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies market. Increased focus of medical professionals on development of alternative therapies and treatments owing to the continually growing prevalence of cancer is projected to create growth opportunities during the forecast period.
Competitive Landscape
Some major key players in the Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market:
- Ambrx
- Catalent Biologics
- Mersana Therapeutics
- Seagen
- Sutro Biopharma
- Iksuda Therapeutics
- Heidelberg Pharma
- LinXis Biopharmaceuticals
- NBE-Therapeutics
- Alteogen
- LegoChem Biosciences
- Araris Biotech AG
- Ajinomoto Co.
- Antikor Biopharma
- Iksuda Therapeutics Ltd
- SynAffix
- Seattle Genetics, Inc
- ImmunoGen
- Immunomedics
- Mersana Therapeutics
- ADC therapeutics
Market Segmentation
The Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market is segmented distribution by generation of technology, type of conjugation, type of linker, type of payment model adopted. Based distribution by generation of technology, the market segmented into third-generation, second-generation and next-generation. Type of Conjugation, the market segmented into Chemical, Chemoenzymatic and Chemical, Type of Linker, the market segmented into Cleavable and non-cleavable, Type of Payment Model Adopted the market segmented into upfront payments and milestone payments.
Recent Developments:
- In January 2024, Ambrx, Johnson & Johnson, declared today that it has reached a final agreement to buy Ambrx Biopharma, Inc., also known as Ambrx, a biopharmaceutical company in clinical stage that uses a unique platform for synthetic biology technology to create and develop next-generation antibody drug conjugates (ADCs). The deal is an all-cash merger, with a total equity value of about $2.0 billion, or $1.9 billion net of estimated cash acquired.
Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market Report Scope
|
Report Attribute |
Specifications |
|
Market size value in 2023 |
USD 1.0 Bn |
|
Revenue Forecast in 2031 |
USD 2.33 Bn |
|
Growth rate CAGR |
CAGR of 11.31 % from 2024 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Distribution by Generation of Technology, Type of Conjugation, Type of Linker, Type of Payment Model Adopted |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Seattle Genetics, Inc., ImmunoGen, Ambrx, Catalent Biologics, Immunomedics, Mersana Therapeutics, Sutro Biopharma, Iksuda Therapeutics, LegoChem Biosciences, LinXis, ADC therapeutics and Other Prominent Players. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
